Articles
MCAS Self-management toolkit
This toolkit contains information about substances in food and in the environment that can affect mast cell activity or trigger MCAS symptoms. It also includes practical advice to help you understand and avoid these triggers, as needed.
MCAS symptom log
The histamine bucket exercise
This histamine bucket is a useful visual aid in trying to understand the impact of factors contributing to histamine levels.
Ask Ingrid app
A free app developed by the Food Intolerance Network, Australian Society for Public Health. It contains comprehensive information about foods containing histamine, sorbitol, gluten, lactose, fructose and FODMAPs.
Baliza.de. Histamine, fructose & co food intolerance app
A smartphone app that provides practical, evidence-based information about foods containing common triggers such as histamine, tyramine, lactose, fructose, sorbitol and fructose.
Monash University FODMAP app
A smartphone app developed by experts at Monash University. Contains detailed information about foods containing FODMAPs as well as a useful symptom tracker feature.
Swiss Interest Group Histamine Intolerance (SIGHI)
SIGHI is an organisation that provides information about histamine-related disorders.
The low histamine chef
Blogs, books and recipes written by the low histamine chef (Yasmina Ykelenstam), a health journalist who has managed her own histamine intolerance for more than 10 years.
Becky's MCAS Journey
An infographic of a patient's experience with MCAS.
Diagnosing MCAS Leaflet
A leaflet discussing diagnostic criteria, biomarker tests and important information for diagnosis.
Mast Cell Action Brochure _ B&W
Cosegregation of postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome
Vadas P, Guzman J, McGillis L, Mittal N, Walsh S. Cosegregation of postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome. Ann Allergy Asthma Immunol. 2020;125(6):719-720. doi:10.1016/j.anai.2020.08.015
The relationship between mast cell activation syndrome, postural tachycardia syndrome and Ehlers-Danlos syndrome
Wang E, Ganti T, Vaou E, Hohler A. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome. Allergy Asthma Proc. 2021;42(3):243-246. doi:10.2500/aap.2021.42.210022
Mast cell activation syndromes and anaphylaxis: Multiple diseases part of the same spectrum
González-de-Olano D, Matito A, Alvarez-Twose I. Mast cell activation syndromes and anaphylaxis: Multiple diseases part of the same spectrum. Ann Allergy Asthma Immunol. 2020;124(2):143-145.e1. doi:10.1016/j.anai.2019.11.023
Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience
Kim JH, Xi S, Ference EH, Ge M, Liu MM, Wrobel BB. Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience. Int Forum Allergy Rhinol. 2020;10(8):996-1000. doi:10.1002/alr.22558
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management
Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7(4):1097-1106. doi:10.1016/j.jaip.2019.02.002
Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.
Jagdis A, Vadas P. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2014;113(1):115-116. doi:10.1016/j.anai.2014.05.001
Timing of response and long term efficacy of Omalizumab in non-clonal mast cell activation syndrome: A case series.
Caminati M, Olivieri E, Nalin F, et al. Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series. Eur J Intern Med. 2020;71:104-106. doi:10.1016/j.ejim.2019.11.010
Mast Cell Activation Disorders
Giannetti A, Filice E, Caffarelli C, Ricci G, Pession A (2021). This article provides an overview of recent scientific findings relating to mast cell disorders, with an emphasis on diagnostic criteria, variability in symptoms and therapeutic strategies for tackling MCAS. It highlights the fact that there is little consensus on biomarkers indicating MCAS and concludes that a more detailed knowledge of the syndrome is necessary for developing effective therapies.
Mast cell activation syndrome: Myths and realities
Zhang S, Bernstein JA. Mast cell activation syndrome: Myths and realities. Allergy Asthma Proc. 2021;42(3):198-204. doi:10.2500/aap.2021.42.210012
Become a friend
Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives.
Donate
Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.
